Vascular Endothelial Growth Factor Receptor-3
"Vascular Endothelial Growth Factor Receptor-3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A vascular endothelial cell growth factor receptor whose expression is restricted primarily to adult lymphatic endothelium. VEGFR-3 preferentially binds the vascular endothelial growth factor C and vascular endothelial growth factor D and may be involved in the control of lymphangiogenesis.
| Descriptor ID |
D040321
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.950.300 D12.776.543.750.630.750.300 D12.776.543.750.750.400.910.300
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Vascular Endothelial Growth Factor Receptor-3".
Below are MeSH descriptors whose meaning is more specific than "Vascular Endothelial Growth Factor Receptor-3".
This graph shows the total number of publications written about "Vascular Endothelial Growth Factor Receptor-3" by people in this website by year, and whether "Vascular Endothelial Growth Factor Receptor-3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2018 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vascular Endothelial Growth Factor Receptor-3" by people in Profiles.
-
Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma. Cell Rep Med. 2021 10 19; 2(10):100411.
-
Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib. Cancer Res. 2019 01 01; 79(1):231-241.